Company: OSRH
Filing Date: 2025-04-22
Form Type: 10-K
Source: 0001213900-25-034116
Chunk: 85

Company: OSR Holdings, Inc.
Filing Date: 2025-04-22
Form: 10-K
Item: Item 1
Chunk 85
---
 of our current
programs. Our monthly spending levels will vary based on new and ongoing development and corporate activities. Because the length of time
and necessary activities associated with the development of our product candidates are highly uncertain, we are unable to estimate the
actual funds we will require for development, marketing and commercialization activities. Our future funding requirements, both near and
long-term, will depend on many factors, including, but not limited to:

●the initiation, progress, timing, costs and results of preclinical
studies and clinical trials for our product candidates, including whether and when to advance our diverse portfolio of product candidates;

●the clinical development plans we establish for these product
candidates;

●the timelines of our clinical trials and the overall costs to
finish the clinical trials;

●the number and characteristics of product candidates that we
develop;

●the outcome, timing and cost of meeting regulatory requirements
established by the FDA, European Medicines Agency and other comparable foreign regulatory authorities;

●the cost of filing, prosecuting, defending and enforcing our
patent claims and other intellectual property rights;

44

●the cost of defending intellectual property disputes, including
patent infringement actions brought by third parties against us or our product candidates;

●the extent to which we enter into additional collaboration agreements
with regard to product discovery or acquire or in-license products or technologies;

●the effect of competing technological and market developments;

●the cost and timing of completion of commercial-scale outsourced
manufacturing activities; and

●the cost of establishing sales, marketing and distribution capabilities
for any product candidates for which we may receive regulatory approval in regions where we choose to commercialize our products on our
own.

Until we can generate sufficient revenue to finance our cash requirements,
which we may never do, we expect to finance our future cash needs through a combination of public or private equity offerings, debt financings,
collaborations, strategic alliances, licensing arrangements and other marketing or distribution arrangements. This additional funding
may not be sufficient for us to fund any of our products through regulatory approval.

To the extent that we raise additional capital through the sale of
common stock or securities convertible or exchangeable into common stock, your ownership interest will be diluted. In addition, any debt
financing may subject us to fixed payment obligations and covenants limiting or restricting our ability to take specific actions, such
as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional capital through marketing and
distribution arrangements or other collaborations